制藥網(wǎng)>產(chǎn)品庫>原料藥中間體、制劑>生物試劑>其它試劑>>Chloroquine試劑

Chloroquine試劑

參考價(jià)	￥500.00-￥550.00

參考價(jià)

￥500.00-￥550.00

具體成交價(jià)以合同協(xié)議為準(zhǔn)

公司名稱杭州昊鑫生物科技股份有限公司
品牌MCE
型號HY-17589A
所在地杭州市
廠商性質(zhì)代理商
更新時(shí)間2023/5/22 12:06:59
訪問次數(shù)245

產(chǎn)品標(biāo)簽:

規(guī)格

10	550.00元	10000 支可售
100	500.00元	10000 支可售

在線詢價(jià) 收藏產(chǎn)品查看電話同類產(chǎn)品

聯(lián)系我們時(shí)請說明是制藥網(wǎng) 上看到的信息，謝謝!

索取相關(guān)資料

公司介紹主營產(chǎn)品

杭州昊鑫生物科技股份有限公司成立于2009年初，是一家面向生命科學(xué)領(lǐng)域，從事科研機(jī)構(gòu)、高校、院所及生產(chǎn)企業(yè)所需科研試劑、耗材，儀器銷售和服務(wù)面向全國。

產(chǎn)品和服務(wù)涵蓋生命科學(xué)研究技術(shù)的諸多方面，提供覆蓋分子生物學(xué)、細(xì)胞生物學(xué)、植物學(xué)、生物化學(xué)、蛋白組學(xué)、免疫學(xué)等領(lǐng)域的實(shí)驗(yàn)產(chǎn)品以及生物技術(shù)服務(wù)等。目前一級代理品牌有：MCE（Medchemexpress）、Biochannel、AATbio、invivogen、Abnova、Atlas、Origene、Biovision、云克隆（Cloud-clone）、艾德萊(Aidlab)、Cayman、Jackson、Epigentek、Prospec、Sciencell、icellbioscience（賽百慷）、hkABCbio、chondrex、Mybiosource、Abbexa、Innovrsrch、HPI、Hitobiotec、Greerlabs，Ostex，4ADI，LDN等。

經(jīng)營理念：以誠信為本，保證產(chǎn)品質(zhì)量求生存，創(chuàng)造企業(yè)核心競爭力求發(fā)展 , 堅(jiān)持用戶至上、服務(wù)至上的原則。

展開顯示更多內(nèi)容

胎牛血清、MCE抑制劑激動(dòng)劑、RNA提取試劑盒、ELISA試劑盒、重組蛋白

產(chǎn)品簡介在線詢價(jià)

CAS號	54-05-7	產(chǎn)地	進(jìn)口
級別	其他

Chloroquine試劑
Chloroquine 是一種廣泛用于瘧疾和類風(fēng)濕性關(guān)節(jié)炎的抗炎試劑。Chloroquine 是自噬 (autophagy) 和 Toll 樣受體 (TLRs) 的抑制劑。Chloroquine 有效抑制 SARS-CoV-2 感染 (EC50=1.13 μM)。

Chloroquine試劑產(chǎn)品信息

生物活性

Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 infection in vitro (EC₅₀=1.13 μM)^[1]^[2]^[3]^[4].

IC₅₀ & Target^[1]^[2][3]^[5]



Plasmodium	Malaria	TLRs	SARS-COV-2	HIV-1

體外研究
(In Vitro)

Chloroquine (CHQ, 20 μM) inhibits IL-12p70 release and reduces Th1-priming capacity of activated human monocyte-derived Langerhans-like cells (MoLC). Chloroquine (20 μM) enhances IL-1–induced IL-23 secretion in MoLC and subsequently increases IL-17A release by primed CD4⁺ T cells^[1]. Chloroquine (25 μM) suppresses MMP-9 mRNA expression in normoxia and hypoxia in parental MDA-MB-231 cells. Chloroquine has cell-, dose- and hypoxia-dependent effects on MMP-2, MMP-9 and MMP-13 mRNA expression^[2]. TLR7 and TLR9 inhibition using IRS-954 or chloroquine significantly reduces HuH7 cell proliferation in vitro^[3].
Chloroquine (0.01-100 μM; 48?hours) potently blocked virus infection (vero E6 cells infected with SARS-CoV-2) at low-micromolar concentration (EC₅₀=1.13?μM). Chloroquine blocks virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

Chloroquine (80 mg/kg, i.p.) does not prevent the growth of the triple-negative MDA-MB-231 cells with high or low TLR9 expression levels in the orthotopic mouse model^[2].
TLR7 and TLR9 inhibition using IRS-954 or chloroquine significantly inhibits tumour growth in the mouse xenograft model. HCC development in the DEN/NMOR rat model is also significantly inhibited by Chloroquine^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01680406	Centers for Disease Control and Prevention\|Ethiopian Health and Nutrition Research Institute\|Federal Minstry of Health of Ethiopia\|Columbia University\|Oromia Regional Health Bureau, Ethiopia\|United States Agency for International Development (USAID)\|Menzies School of Health Research	Plasmodium Vivax Infection	October 2012	Phase 4
NCT00677833	Pfizer	Malaria, Falciparum	June 2008	Phase 2\|Phase 3
NCT04353336	Tanta University	Coronavirus Infection	March 23, 2020	Phase 2\|Phase 3